Is SARS-CoV-2 important for multiple sclerosis?

被引：0
|
作者：
Chyzhyk, V. [1 ]
Sialitski, M.
Boika, A. [1 ]
Bahamaz, V.
Mazurenka, K. [1 ]
Ponomarev, V. [1 ]
机构：
[1] Dept Neurol & Neurosurg, Minsk, BELARUS
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-084
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [41] SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort
    van Kempen, Zoe L. E.
    Strijbis, Eva M. M.
    Al, Marissa M. C. T.
    Steenhuis, Maurice
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    JAMA NEUROLOGY, 2021, 78 (07) : 880 - 882
  • [42] Vaccine Hesitancy in Patients With Multiple Sclerosis Preparing for the SARS-CoV-2 Vaccination Challenge
    Diem, Lara
    Friedli, Christoph
    Chan, Andrew
    Salmen, Anke
    Hoepner, Robert
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
  • [43] Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2
    Schreiner, Teri
    Wilson-Murphy, Molly
    Mendelt-Tillema, Jan
    Waltz, Michael
    Codden, Rachel
    Benson, Leslie
    Gorman, Mark
    Goyal, Manu
    Krupp, Lauren
    Lotze, Tim
    Mar, Soe
    Ness, Jayne
    Rensel, Mary
    Roalstad, Shelly
    Rodriguez, Moses
    Rose, John
    Shukla, Nikita
    Waubant, Emmanuelle
    Wheeler, Yolanda
    Casper, T. Charles
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (4-5) : 576 - 584
  • [44] Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis
    Schraad, Muriel
    Uphaus, Timo
    Runkel, Stefan
    Hitzler, Walter
    Bittner, Stefan
    Zipp, Frauke
    EBIOMEDICINE, 2023, 87
  • [45] Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
    Gyang, Tirisham, V
    Evans, John P.
    Miller, Joseph S.
    Alcorn, Kariss
    Peng, Juan
    Bell, Erica H.
    Zeng, Cong
    Gumina, Richard
    Liu, Shan-Lu
    Segal, Benjamin M.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2022, 8 (01)
  • [46] Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
    M. Allman
    E. Tallantyre
    N. P. Robertson
    Journal of Neurology, 2022, 269 : 2259 - 2261
  • [47] Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
    Allman, M.
    Tallantyre, E.
    Robertson, N. P.
    JOURNAL OF NEUROLOGY, 2022, 269 (04) : 2259 - 2261
  • [48] Do multiple sclerosis drugs decrease the risk of a severe SARS-CoV-2 infection?
    Ramo Tello, C.
    Carbonell Gisbert, J.
    Presas Rodriguez, S.
    Soler Juhe, S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 684 - 684
  • [49] SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
    Amor, Sandra
    Baker, David
    Khoury, Samia J.
    Schmierer, Klaus
    Giovanonni, Gavin
    ANNALS OF NEUROLOGY, 2020, 87 (06) : 794 - 797
  • [50] Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis
    Laroni, A.
    Capaia, M.
    Lusi, V.
    Casella, V.
    Della Valle, I.
    Franciotta, D.
    Sormani, M. P.
    Vigo, T.
    Inglese, M.
    Lapucci, C.
    Grifoni, A.
    Sette, A.
    Raposo, C.
    De Palma, R.
    Fenoglio, D.
    Pedotti, R.
    Uccelli, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 623 - 624
12345